Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels
(800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with relapsed
or refractory acute myeloid leukemia (AML). Additional dose levels beyond 1200 mg/day may be
considered based on safety and efficacy observations.